For US #HCPs at #ASCO25: see Dr. Philippe Moreau share analysis from the Phase 3 PERSEUS trial of sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed #MultipleMyeloma.

For US #HCPs at #ASCO25: watch Dr. Niels van de Donk share initial results from the Phase 1 first-in-human study in patients with relapsed or refractory #MultipleMyeloma. clinicaltrials.gov/study/NCT05652…

For US #HCPs at #ASCO25: see Dr. Gerhardt Attard present late-breaking data from the Phase 3 AMPLITUDE trial in metastatic castration-sensitive #ProstateCancer patients with alterations in homologous recombination repair genes.

For US #HCPs at #ASCO25: Dr. Peter Voorhees will share long-term remission and survival results from the Phase 1b/2 CARTITUDE-1 study in patients with relapsed or refractory #MultipleMyeloma.

For US #HCPs who attended #ASCO25, click below to view J&J presentations. #Oncology

New publication in the Journal of Clinical Oncology: Dr. Mark Stein (Mark Stein) shares Phase 1 trial results for our first-in-class, T-cell engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of #ProstateCancer cells. For US #HCPs.

For US #HCPs attending European Hematology Association’s 2025 congress this week: view the timing of our presentations by clicking below. #Hematology #EHA2025

For US #HCPs at #EHA2025, click below to view #Hematology posters from J&J in-person or online.

For US #HCPs at #EHA2025: watch Dr. Andrew Wei present results from the Phase 1b study in patients with chemo-ineligible newly diagnosed and relapsed or refractory acute myeloid #Leukemia harboring KMT2A or NPM1 alterations. clinicaltrials.gov/study/NCT05453…

For US #HCPs at #EHA2025: join Dr. Sundar Jagannath as he shares long-term remission and survival results from a follow-up study in CARTITUDE-1 patients with relapsed or refractory #MultipleMyeloma. clinicaltrials.gov/study/NCT05201…

For US #HCPs at #EHA2025: watch Dr. Matthew Ku present results from a global Phase 1b study of a bi-specific chimeric antigen receptor T-Cell therapy in patients with relapsed or refractory large B-Cell #Lymphoma. clinicaltrials.gov/study/NCT05421…

For US #HCPs at #EHA2025: Dr. Rakesh Popat (Rakesh Popat) will share results from a first-in-human Phase 1 study of a novel, next-generation trispecific antibody, in patients with relapsed or refractory #MultipleMyeloma. clinicaltrials.gov/study/NCT05652…

For US #HCPs at #EHA2025: see Dr. Aurore Perrot (Aurore Perrot) present initial safety and efficacy results from the Phase 1b TRIMM-3 study in patients with relapsed or refractory #MultipleMyeloma.

For US #HCPs at #EHA2025: join Dr. Shaji Kumar (Shaji Kumar) as he shares results from the Phase 2 RedirecTT-1 study in patients with relapsed or refractory #MultipleMyeloma and extramedullary disease.

For US #HCPs at #EHA2025: don’t miss Dr. Paolo Ghia present a final analysis from the Phase 2 CAPTIVATE study in patients with chronic lymphocytic #Leukemia or small lymphocytic #Lymphoma.

For US #HCPs: European Hematology Association’s 2025 congress has come to a close. Click below to view J&J presentations. #Hematology #EHA2025

Read a peer-reviewed publication in the European Urology Oncology: Dr. Kim Chi shares Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial in patients with metastatic castration-resistant #ProstateCancer. For US #HCPs.

Read a peer-reviewed publication in Frontiers: Dr. Alfred Garfall, Dr. Elena Zamagni, and Dr. Yi Lin (Yi Lin) share a roadmap to implementing outpatient administration of bispecific antibodies in patients with relapsed or refractory #MultipleMyeloma. For US #HCPs.

New publication in the Journal of Clinical Oncology: Dr. Siamak Daneshmand, Dr. Andrea Necchi (Andrea Necchi), and Dr. Félix Ramos (Félix Guerrero-Ramos) share results from the Phase IIb SunRISe-1 study for patients with BCG–unresponsive high-risk non–muscle-invasive #BladderCancer. For US #HCPs.

Now recruiting: A Phase 1 clinical study (NCT07107230) in patients with histologically confirmed unresectable, locally advanced, or metastatic non-small cell #LungCancer, colorectal #Carcinoma, or head and neck squamous cell carcinoma. For US #HCPs. clinicaltrials.gov/study/NCT07107…